Johnson & Johnson Says Talvey,Tecvayli Shows Deep,Durable Responses In Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease
June 15 (Reuters) - Johnson & Johnson JNJ.N:
INVESTIGATIONAL COMBINATION OF FIRST-IN-CLASS BISPECIFICS TALVEY® AND TECVAYLI® SHOWS DEEP AND DURABLE RESPONSES IN HEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE
JOHNSON & JOHNSON - PHASE 2 STUDY SHOWS 78.9% OVERALL RESPONSE RATE
JOHNSON & JOHNSON - NOVEL APPROACH SHOWS POTENTIAL IN EXTRAMEDULLARY DISEASE PATIENTS
JOHNSON & JOHNSON - COMBINATION THERAPY ACHIEVES 78.9% ORR, 54.4% COMPLETE RESPONSE
JOHNSON & JOHNSON - 61% OF PATIENTS PROGRESSION FREE AND ALIVE AT ONE YEAR
JOHNSON & JOHNSON - 64.1% MAINTAIN RESPONSE, 74.5% ALIVE AT ONE YEAR
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Is Meta Platforms Stock a Smart Buy Ahead of Q1 2026 Earnings? Unpacking AI Growth and Investment Potential

Tradingkey








